1.Welsh JW，Komaki R，Amini A，et al.Phase Ⅱ trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol，2013，31（7）：895-902.

2.Sperduto PW，Wang M，Robins HI，et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases：Radiation Therapy Oncology Group 0320.Int J Radiat Oncol Biol Phys，2013，85（5）：1312-1318.

3.Buter J and Giaccone G. EGFR inhibitors in lung cancer. Oncology（Williston Park），2005，19（13）：1707-1711；discussion 1711-1712，1720-1723.

4.Janne PA. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. Semin Oncol，2005，32（6）：S9-15.

5.Cappuzzo F，Finocchiaro G，Metro G，et al. Clinical experience with gefitinib：an update. Crit Rev Oncol Hematol，2006，58（1）：31-45.

6.Berger LA，Riesenberg H，Bokemeyer C，et al. CNS metastases in non-small-cell lung cancer：current role of EGFR-TKI therapy and future perspectives. Lung Cancer，2013，80（3）：242-248.

7.Chen X，Liu Y，Roe OD，et al. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage nonsmall cell lung cancer：a systematic review. PLoS One，2013，8（3）：e59314.

8.D’Arcangelo M and Cappuzzo F. Erlotinib in the first-line treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther，2013，13（5）：523-533.

9.Liu HB，Wu Y，Lv TF，et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer：a systematic review and meta-analysis. PLoS One，2013，8（1）：e55128.

10.Cadranel J，Ruppert AM，Beau-Faller M，et al. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Crit Rev Oncol Hematol，2013，88（3）：477-493.

11.Karachaliou N，Mayo C，Costa C，et al. KRAS mutations in lung cancer. Clin Lung Cancer，2013，14（3）：205-214.

12.Martin P，Leighl NB，Tsao MS，et al. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol，2013，8（5）：530-542.

13.Carlson JJ，Garrison LP，Ramsey SD，et al.Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy：a systematic review and meta-analysis. J Cancer Res Clin Oncol，2009，135（11）：1483-1493.

14.Dahabreh IJ，Linardou H，Kosmidis P，et al. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment：a systematic review and meta-analysis in non-small-cell lung cancer. Ann Oncol，2011，22（3）：545-552.

15.Linardou H，Dahabreh IJ，Bafaloukos D，et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol，2009，6（6）：352-366.

16.Paz-Ares L，Soulieres D，Melezinek I，et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations：pooled analysis. J Cell Mol Med，2010，14（1-2）：51-69.

17.Siegel R，Naishadham D and Jemal A.Cancer statistics，2013.CA Cancer J Clin，2013，63（1）：11-30.

18.Hanna N，Shepherd FA，Fossella FV，et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol，2004，22（9）：1589-1597.

19.Paez JG，Janne PA，Lee JC，et al. EGFR mutations in lung cancer：correlation with clinical response to gefitinib therapy. Science，2004，304（5676）：1497-1500.

20.Lynch TJ，Bell DW，Sordella R，et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med，2004，350（21）：2129-2139.

21.Kim TY，Han SW and Bang YJ.Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer：Asian perspectives. Expert Rev Mol Diagn，2007，7（6）：821-836.

22.Soda M，Choi YL，Enomoto M，et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature，2007，448（7153）：561-566.

23.Uramoto H and Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer，2007，96（6）：857-863.

24.DeSantis CE，Lin CC，Mariotto AB，et al. Cancer treatment and survivorship statistics，2014.CA Cancer J Clin，2014，64（4）：252-271.

25.Rolfo C，Giovannetti E，Hong DS，et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev，2014，40（8）：990-1004.

26.Ding D，Yu Y，Li Z，et al. The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients：a metaanalysis. Onco Targets Ther，2014（7）：387-393.

27.Ulivi P，Zoli W，Capelli L，et al. Target therapy in NSCLC patients：Relevant clinical agents and tumour molecular characterisation. Mol Clin Oncol，2013，1（4）：575-581.

28.Brugger W，Thomas M. EGFR-TKI resistant non-small cell lung cancer（NSCLC）：new developments and implications for future treatment. Lung Cancer，2012，77（1）：2-8.

29.Burel-Vandenbos F，Ambrosetti D，Coutts M，et al. EGFR mutation status in brain metastases of non-small cell lung carcinoma. J Neurooncol，2013，111（1）：1-10.

30.Petrelli F，Borgonovo K，Cabiddu M，et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer：a meta-analysis of 13 randomized trials. Clin Lung Cancer，2012，13（2）：107-114.

31.Oxnard GR，Binder A and Janne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol，2013，31（8）：1097-1104.

32.Soffietti R，Trevisan E and Ruda R. Targeted therapy in brain metastasis. Curr Opin Oncol，2012，24（6）：679-686.

33.Metro G，Finocchiaro G，Toschi L，et al. Epidermal growth factor receptor（EGFR） targeted therapies in nonsmall cell lung cancer（NSCLC）. Rev Recent Clin Trials，2006，1（1）：1-13.

34.Bergot E，Levallet G，Creveuil C，et al. ［Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers：Methodological issues］. Presse Med，2011，40（4 Pt 1）：379-388.

35.D’Incecco A and Cappuzzo F. Gefitinib for non-small-cell lung cancer treatment. Expert Opin Drug Saf，2011，10（6）：987-996.

36.Kobayashi K and Hagiwara K. Epidermal growth factor receptor（EGFR） mutation and personalized therapy in advanced nonsmall cell lung cancer（NSCLC）. Target Oncol，2013，8（1）：27-33.

37.Merlo V，Longo M，Novello S，et al. EGFR pathway in advanced non-small cell lung cancer. Front Biosci（Schol Ed），2011，3：501-517.

38.Batus M，Fidler MJ and Bonomi PD. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther，2010，10（10）：1589-1599.

39.Jonker DJ，Rosen LS，Sawyer MB，et al. A phase I study to determine the safety，pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor，brivanib，in patients with advanced or metastatic solid tumors. Ann Oncol，2011，22（6）：1413-1419.

40.Wang Y，Liu H and Chen J. The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs. Zhongguo Fei Ai Za Zhi，2010，13（4）：375-379.

41.Shepherd FA，Rodrigues Pereira J，Ciuleanu T，et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med，2005，353（2）：123-132.

42.Riess JW and Neal JW. Targeting FGFR，ephrins，Mer，MET，and PDGFR-alpha in non-small cell lung cancer. J Thorac Oncol，2011，6（11 Suppl 4）：S1797-1798.

43.Mok TS，Wu YL，Thongprasert S，et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med，2009，361（10）：947-957.

44.Maemondo M，Inoue A，Kobayashi K，et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med，2010，362（25）：2380-2388.

45.Zhou C，Wu YL，Chen G，et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer（OPTIMAL，CTONG-0802）：a multicentre，open-label，randomised，phase 3 study. Lancet Oncol，2011，12（8）：735-742.

46.Rosell R，Carcereny E，Gervais R，et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer（EURTAC）：a multicentre，open-label，randomised phase 3 trial. Lancet Oncol，2012，13（3）：239-246.

47.Mitsudomi T，Morita S，Yatabe Y，et al. Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harbouring mutations of the epidermal growth factor receptor（WJTOG3405）：an open label，randomised phase 3 trial. Lancet Oncol，2010，11（2）：121-128.

48.Cross DA，Ashton SE，Ghiorghiu S，et al. AZD9291，an irreversible EGFR-TKI，overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov，2014，4（9）：1046-1061.

49.Ye X，Zhu ZZ，Zhong L，et al. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation：truth or artifact? J Thorac Oncol，2013，8（9）：1118-1120.

50.Lenferink AE，Pinkas-Kramarski R，van de Poll ML，et al. Differential endocytic routing of homo- and heterodimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J，1998，17（12）：3385-3397.

51.Walter AO，Sjin RT，Haringsma HJ，et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov，2013，3（12）：1404-1415.

52.Cortot AB，Repellin CE，Shimamura T，et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res，2013，73（2）：834-843.

53.Sequist LV，Goldman JW，Wakelee HA，et al. Efficacy of Rociletinib（CO-1686） in Plasma-genotyped T790M-positive NSCLC Patients. In：American society of clinical oncology，2015，Abstract 8001.

54.Janne PA，Yang JC，Kim DW，et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med，2015，372（18）：1689-1699.

55.Ramalingam SS，Yang JC. AZD9291，a mutant-selective EGFR inhibitor，as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer（NSCLC）：Results from a phase 1 expansion cohort. In：American society of clinical oncology，2015，Abstract 8000.

56.吴一龙，杨衿记，林嘉颖，等.吉非替尼靶向治疗非小细胞肺癌的临床研究.中华结核和呼吸杂志，2007，30（2）：98-102.

57.徐建明，李月敏，刘晓晴，等.吉非替尼治疗晚期非小细胞肺癌.中华肿瘤杂志，2007，29（1）：66-69.

58.张阳，张力，徐菲，等.吉非替尼记名供药计划（EAP）治疗晚期非小细胞肺癌患者的临床研究结果.癌症，2006，25（12）：1561-1564.

59.张莉，于世英.吉非替尼单药治疗晚期非小细胞肺癌.中华肿瘤杂志，2006，28（7）：539-541.

60.霍伟，冯仲珉，赵卫红，等.吉非替尼治疗晚期非小细胞肺癌64例.临床肿瘤学杂志，2005，10（1）：4-7.

61.杨鹭，刘叙仪，方健，等.吉非替尼治疗91例晚期非小细胞肺癌疗效分析.中华肿瘤杂志，2006，28（6）：474-477.

62.管忠震，张力，李龙芸，等.吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究.癌症，2005，24（8）：980-984.

63.蒋国樑，洪小南，樊旼，等.吉非替尼（Iressa）治疗手术、放疗、化疗治疗后失败的非小细胞肺癌的初步报告.中国肺癌杂志，2004，7（4）：305-308.

64.Mitsudomi T，Tsai C，Shepherd F，et al. AZD9291 in pre-treated T790M positive advanced NSCLC：AURA 2 Phase Ⅱ study.Presented at：16 ^th World Conference on Lung Cancer.Abstract 1406.